RecruitingPhase 2NCT06831058
A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
Studying Immune-mediated thrombotic thrombocytopenic purpura
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Minnesota
- Principal Investigator
- Marshall Mazepa, MDUniversity of Minnesota
- Intervention
- efgartigimod(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- University of Minnesota, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06831058 on ClinicalTrials.govOther trials for Immune-mediated thrombotic thrombocytopenic purpura
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT05046717Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic PurpuraFundación Española de Hematología y Hemoterapía
- ACTIVE NOT RECRUITINGNCT04985318Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTPUniversity of Cologne
See all trials for Immune-mediated thrombotic thrombocytopenic purpura →